PharmAust Limited

PharmAust Limited Clinical-stage company developing targeted cancer therapeutics to address human & animal healthcare.

PharmAust Ltd (PAA) is a clinical-stage company developing targeted cancer therapeutics to address both human and animal healthcare. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, which is a highly successful contract medicinal chemistry company that generates significant annual revenues. PAA’s lead drug candidate is Monepantel (MPL), a small molecule currently registered and marketed as a treatment for parasite infections in food chain animals. PharmAust is independently developing monepantel as a safe and potent modulator of the mTOR pathway, which plays a pivotal role in driving many cancers. PharmAust has been granted multiple ‘methods of use’ patents covering the novel anti-cancer activity of Monepantel.

Address

Suite 116, 1 Kyle Way
Perth, WA
6010

Telephone

+61892026814

Website

Alerts

Be the first to know and let us send you an email when PharmAust Limited posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category